CoChat
Sign Up
Cited by 70Liver Disease Diagnosis and TreatmentPharmacology and Obesity TreatmentBariatric Surgery and Outcomes

The DOI matches its Crossref record; the references it cites are not checked yet.

Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis

Open access
Wang, Hu, Wang, Li, Cheng, Yujia, Xia, Zhiqing, Liao, Yifeng, Cao, Jiang·2018·Biomedical Reports
DOI 10.3892/br.2018.1100PMC PMC6007047
Open this paper in CoChat — free accountOpen PDF

Abstract

In the present meta-analysis, the efficacy and safety of orlistat in the treatment of non-alcoholic fatty liver (NAFLD) and non-alcoholic steatohepatitis (NASH) were evaluated. PubMed, Embase, the Cochrane Library, Web of Science, and Wan Fang data were searched for controlled trials of orlistat in patients with NAFLD or NASH, published before August 2017. Three randomized controlled trials and four single-arm trials were included. The involved participants with NAFLD or NASH (330 patients) were analyzed for clinical outcomes including alteration in hepatic histological variables and biomarkers of liver function. Improvements were observed in levels of alanine aminotransferase [standard mean difference (SMD)=-1.41; P=0.01], aspartate aminotransferase (SMD=-2.06; P=0.0005), γ-glutamyl transpeptidase (SMD=-1.91; P=0.05), glucose [mean difference (MD)=-0.51; P=0.01], triglycerides (MD=-0.93; P=0.01), homeostasis model assessment of insulin resistance index (MD=-1.05; P=0.04) and body mass index (MD=-1.97; P=0.02), but not in liver fibrosis score (SMD=-0.14; P=0.71). On sub-analyses of the different patient groups, no significant differences were observed in patients with NASH. Taken together, these findings demonstrate that orlistat could serve as a therapeutic drug to improve biochemical indicators of liver damage, but not as first-choice drug for the management of NAFLD or NASH; thus suggesting a novel palliative drug only for the treatment of NAFLD.

Overview

Integrity signals

Registry

Crossref · 10.3892/br.2018.1100

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists haven’t been fetched yet

References 37 · Cited by 70

Research works printed but not linked: 31

  1. Lazo, 2008, The epidemiology of nonalcoholic fatty liver disease: A global perspective, Semin Liver Dis, 28, 339, 10.1055/s-0028-1091978 · DOI
  2. Zhu, 2015, Prevalence of nonalcoholic fatty liver disease and economy, Dig Dis Sci, 60, 3194, 10.1007/s10620-015-3728-3 · DOI
  3. Vanni, 2010, From the metabolic syndrome to NAFLD or vice versa?, Dig Liver Dis, 42, 320, 10.1016/j.dld.2010.01.016 · DOI
  4. Li, 2016, Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies, Obes Rev, 17, 510, 10.1111/obr.12407 · DOI
  5. Zhao, 2017, Research on the natural history of non-alcoholic fatty liver disease should be taken seriously, Zhonghua Gan Zang Bing Za Zhi, 25, 81
  6. Bhala, 2011, The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study, Hepatology, 54, 1208, 10.1002/hep.24491 · DOI
  7. Duvnjak, 2009, Therapy of nonalcoholic fatty liver disease: Current status, J Physiol Pharmacol, 60, 57
  8. Narayanaswami, 2017, Obesity: Current and potential pharmacotherapeutics and targets, Pharmacol Ther, 170, 116, 10.1016/j.pharmthera.2016.10.015 · DOI
  9. Kushner, 2002, Medical management of obesity, Semin Gastrointest Dis, 13, 123
  10. Ali Khan, 2017, Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients, Ther Clin Risk Manag, 13, 139, 10.2147/TCRM.S124621 · DOI
  11. Chen, 2006, The analysis of the efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat, Chin J Clin Hepatol, 22, 123
  12. Harrison, 2004, A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients, Aliment Pharmacol Ther, 20, 623, 10.1111/j.1365-2036.2004.02153.x · DOI
  13. Fernández, 2016, Progesterone causes metabolic changes involving aminotransferases and creatine kinase in cryopreserved bovine spermatozoa, Anim Reprod Sci, 164, 90, 10.1016/j.anireprosci.2015.11.016 · DOI
  14. Bruinsma, 2015, Warm ischemic injury is reflected in the release of injury markers during cold preservation of the human liver, PLoS One, 10, e0123421, 10.1371/journal.pone.0123421 · DOI
  15. Filippatos, 2008, Orlistat-associated adverse effects and drug interactions: A critical review, Drug Saf, 31, 53, 10.2165/00002018-200831010-00005 · DOI
  16. Zelber-Sagi, 2006, A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 4, 639, 10.1016/j.cgh.2006.02.004 · DOI · Paper page
  17. Moher, 2010, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, Int J Surg, 8, 336, 10.1016/j.ijsu.2010.02.007 · DOI · Paper page
  18. Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z · DOI · Paper page
  19. Li, 2014, Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies, J Gastroenterol Hepatol, 29, 42, 10.1111/jgh.12428 · DOI
  20. Fan, 2004, Clinical study of obesity associated non-alcoholic fatty liver disease, Chin Hepatol, 9, 155
  21. Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial, Hepatology, 49, 80, 10.1002/hep.22575 · DOI · Paper page
  22. Hussein, 2007, Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH), Dig Dis Sci, 52, 2512, 10.1007/s10620-006-9631-1 · DOI
  23. Angulo, 2007, The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI
  24. Mahboub, 2016, Gradual rewarming with gradual increase in pressure during machine perfusion after cold static preservation reduces kidney ischemia reperfusion injury, PLoS One, 11, e0152006, 10.1371/journal.pone.0152006 · DOI
  25. Tilg, 2010, Weight loss: Cornerstone in the treatment of non-alcoholic fatty liver disease, Minerva Gastroenterol Dietol, 56, 159
  26. Gabriel, 2012, Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals, Int J Endocrinol Metab, 10, 458, 10.5812/ijem.2920 · DOI
  27. Nakou, 2010, The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients, Lipids, 45, 445, 10.1007/s11745-010-3409-0 · DOI · Paper page
  28. Kujawska-Łuczak, 2017, The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study, Arch Med Sci, 13, 725, 10.5114/aoms.2016.62014 · DOI · Paper page
  29. Scheen, 2014, Combating the dual burden: Therapeutic targeting of common pathways in obesity and type 2 diabetes, Lancet Diabetes Endocrinol, 2, 911, 10.1016/S2213-8587(14)70004-X · DOI
  30. Smith-Marsh, 2013, Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance, Drugs Today (Barc), 49, 499, 10.1358/dot.2013.49.8.2002839 · DOI
  31. Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 142, 1592, 10.1053/j.gastro.2012.04.001 · DOI

Metadata

Authors
Wang, H., Wang, L., Cheng, Y., Xia, Z., Liao, Y., & Cao, J.
Affiliations
  • Xuzhou Medical College (CN)
  • Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China
ORCID
Venue
Biomedical Reports
Publisher
Spandidos Publications
Published
2018-05-22
Volume
9
Issue
1
Pages
90-96
ISSN
  • 2049-9434 (ISSN-L)
  • 2049-9442
DOI
10.3892/br.2018.1100
PMC
PMC6007047
OpenAlex
W2804448616
Cited by
70
References
37
Citations by year
2026: 1 · 2025: 8 · 2024: 11 · 2023: 10 · 2022: 12 · 2021: 9 · 2020: 11 · 2019: 5 · 2018: 2
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • Biomedical Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
orlistat, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipase inhibitors, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, insulin resistance, triglycerides, body mass index, liver fibrosis, drug safety and efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review